GlassScriptPhysician profile
Robert L Reid
NPI 1790753325
$2,437.39
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $134 · 2021: $34.13 · 2022: $1,569 · 2023: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $1,567.23 | 2022-2023 | Precisetumor, Myrisk |
| Janssen Biotech, INC. | $134.69 | 2019-2020 | |
| Genentech USA, INC. | $102.28 | 2019-2023 | Polivy, Lunsumio, Tecentriq |
| Amgen INC. | $102.06 | 2019-2023 | Blincyto, Kyprolis |
| Novartis Pharmaceuticals Corporation | $92.41 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $63.45 | 2019-2023 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $53.16 | 2022-2023 | Epkinly, Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $40.63 | 2019-2020 | |
| Celgene Corporation | $39.65 | 2020-2022 | |
| Incyte Corporation | $37.58 | 2019-2022 | |
| Daiichi Sankyo INC. | $35.21 | 2022-2023 | Injectafer |
| Tersera Therapeutics LLC | $29.91 | 2022 | |
| Lilly USA, LLC | $23.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.93 | 2019 | |
| Pfizer INC. | $21.79 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $21.33 | 2023 | Krazati |
| Array Biopharma INC | $20.15 | 2023 | Mektovi, Braftovi, Xalkori |
| Amag Pharmaceuticals, INC. | $17.67 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.